Long-term registry of adults with generalized myasthenia gravis treated with C5 inhibitors
Collects long-term data on safety and outcomes in adults with generalized myasthenia gravis.
Plain-language title generated from the registry record
Registry title: Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
Key facts
- Where
- Vienna, AustriaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The registry is looking for adults with generalized myasthenia gravis who are treated with, or were previously treated with, an Alexion C5 inhibitor therapy such as Soliris or Ultomiris.
- Age
- 18 Years or older
- Sex
- All sexes can join.
- Disease stage
- Diagnosis of generalized myasthenia gravis (gMG).
- Earlier treatment
- Must be treated with Alexion C5 inhibitor therapy at enrollment. People treated earlier with Soliris or Ultomiris and then taken off it can also join.
Main reasons for not taking part
- Currently taking part in an Alexion-sponsored interventional clinical study for gMG treatment
- Cannot give signed informed consent
- No myasthenia gravis historical data available, such as MG-ADL and MGFA class
Read by machine on 9 November 2026.
Where in Austria
- ViennaVienna, AustriaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Alexion Pharmaceuticals, Inc.
- Trial code
- NCT04202341
- Record updated
- 18 February 2026
- Original description
Long-term, multicenter, multinational, observational, registry of patients with gMG that is designed to collect data on clinical outcomes and safety in patients prescribed Alexion C5 inhibitor therapies (C5IT) such as eculizumab (Soliris®) and ravulizumab (Ultomiris®).Read full original descriptionShow less
Long-Term, Observational, Global Registry of Patients With Generalized Myasthenia Gravis Who Have Received Treatment With Complement C5 Inhibition Therapies (C5ITs)
Long-term, multicenter, multinational, observational, registry of patients with gMG that is designed to collect data on clinical outcomes and safety in patients prescribed Alexion C5 inhibitor therapies (C5IT) such as eculizumab (Soliris®) and ravulizumab (Ultomiris®).
Inclusion: Participants with a diagnosis of gMG who are treated with Alexion C5IT at the time of enrollment, including patients previously treated with Soliris or Ultomiris and withdrawn from treatment; Capable of giving signed informed consent, which includes compliance with the protocol requirements and restrictions; Participants must have myasthenia gravis historical data, such as MG-ADL and MGFA class, available to be enrolled in the Registry.
Exclusion: Participants currently enrolled in an Alexion-sponsored interventional clinical study for treatment of gMG cannot be enrolled in the Alexion gMG Registry while enrolled/participating in the clinical study for gMG therapy.